nantkwest

Publications

Peer-Reviewed Publications

2019

taNK and t-haNK Paper

CAR-Expressing Natural Killer Cells for Cancer Retargeting
Stephan Kloessa, c Anna Kretschmera Lilly Stahla Stephan Frickea Ulrike Koehla–c

haNK Paper (upcoming)

Overcoming hypoxia-induced functional suppression of NK cells; Kristy Solocinski, Michelle R. Padget, Fabiola Cecchi, Todd Hembrough, Steve Benz, Shahrooz Rabizadeh, Patrick Soon-Shiong, Jeffrey Schlom, and James W. Hodge; Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, NantOmics, LLC, Rockville, MD, NantOmics, LLC, Santa Cruz, CA, NantKwest, Inc., Culver City, CA

haNK Paper

Giles, A. J., Hao, S., Padget, M., Song, H., Zhang, W., Lynes, J., . . . Park, D. M. (2019). Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK. JCI Insight, 4(20). doi:10.1172/jci.insight.130688

taNK Paper

Ravi, D., Sarkar, S., Purvey, S., Passero, F., Beheshti, A., Chen, Y., . . . Evens, A. M. (2019). Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma. Leukemia. doi:10.1038/s41375-019-0663-x

t-haNK Paper (upcoming)

PD-L1-targeting high-affinity natural killer cells (PD-L1 CAR haNK) induce direct antitumor effects and target suppressive MDSC populations; Kellsye P. Fabian, Michelle R. Padget, Renee N. Donahue, Kristen Solocinski, Yvette Robbins, Clint T. Allen, John H. Lee, Shahrooz Rabizadeh,Patrick Soon-Shiong, Jeffrey Schlom, and James W. Hodge; Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

t-haNK Paper (upcoming)

Targeting PD-L1 With Chimeric Antigen Receptor Modified NK Cells Induces Tumor Control and Reduction of PD-L1 High Immune Populations; Yvette Robbins, Sarah Greene, Jay Friedman, Paul E. Clavijo, Kellsye P. Fabian, Michelle R. Padget, Houssein Abdul Sater, John H. Lee, Patrick Soon-Shiong, James Gulley, Jeffrey Schlom, James W. Hodge, Clint T. Allen; Translational Tumor Immunology Program, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD; Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD; NantKwest, Culver City, CA; Genitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Baltimore, MD

haNK Poster

Innate and adaptive immunotherapy: An orchestration of immunogenic cell death by overcoming immune suppression and activating NK and T-cell therapy in patients with third line or greater Triple-Negative Breast Cancer (TNBC); Chaitali Singh Nangia, Mira Kistler, Leonard S. Sender, John H. Lee, Frank R. Jones, Omid Jafari, Patrick Soon-Shiong; Chan Soon Shiong Institute for Medicine, Laguna Hills, CA; Chan Soon Shiong Institute of Medicine, El Segundo, CA; Children’s Hospital of Orange County, Laguna Hills, CA; Sanford Health, Sioux Falls, SD; Etubics Corporation, Seattle, WA; Medical Imaging Center of Southern California, Santa Monica, CA; NantKwest, Culver City, CA

haNK Poster

NANT Cancer Vaccine (NCV): An Orchestration of Immunogenic Cell Death by Overcoming Immune Suppression and Activating Natural Killer (NK) and T Cell Therapy in Patients with Greater than 3rd Line Metastatic Pancreatic Cancer; Tara Seery, Arvind Shinde, Mira Kistler, Lennie Sender, Anand Annamalai, Omid Jafari, Frank Jones, John H. Lee, Patrick Soon-Shiong; Chan Soon Shiong Institute for Medicine, Laguna Hills, CA; Chan Soon Shiong Institute of Medicine, El Segundo, CA; Chan Soon Shiong Institute for Medicine, El Segundo, CA; NantKwest, Culver City, CA; St. Vincent Medical Center, Los Angeles, CA; St. Vincent’s Medical Center, Los Angeles, CA; Jan 2019

haNK Poster

NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly-Informed Integrated Immunotherapy Combining Innate High-Affinity Natural Killer (haNK) Cell Therapy with Adenoviral & Yeast-based Vaccines and Immune Checkpoint Inhibitor to Induce T-Cell Responses in Subjects with TNBC Who Have Progressed on or after Standard-of-Care Therapy; Mira Kistler, Lennie Sender, Chaitali Nangia, Christina To, Sandeep B. Reddy, Sadanand Vodala, Andrew Nguyen, Noe Rodriguez, Peter Sieling, Charles Vaske, Jon Van Lew, John H. Lee, Kayvan Niazi, Shahrooz Rabizadeh, Patrick Soon-Shiong; Chan Soon Shiong Institute for Medicine, El Segundo, CA; NantKwest, Culver City, CA; NantHealth, Culver City, CA; ImmunityBio LLC, Culver City, CA; Dec 2019; San Antonio Breast Cancer Symposium 2019

aNK Abstract and Oral

Final results from a phase 2 study using off-the-shelf activated natural killer (aNK) Cells in combination with N-803, an IL-15 superagonist, in patients with metastatic Merkel cell carcinoma (MCC); Shailender Bhatia, Candice D. Church, Kelly G. Paulson, Robert H. Pierce, Paul Nghiem, John H. Lee, Bridget M. Adcock, Patrick Soon-Shiong, Sunandana Chandra; University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle WA; ImmunityBio, Inc., Nantkwest Inc., Culver City, CA; Northwestern University Feinberg School of Medicine, Chicago, IL; Nov 2019; SITC

2018

taNK Paper

Nowakowska, P., Romanski, A., Miller, N., Odendahl, M., Bonig, H., Zhang, C., . . . Tonn, T. (2018). Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies. Cancer Immunol Immunother, 67(1), 25-38. doi:10.1007/s00262-017-2055-2

taNK Paper

Williams, B. A. W., X. H.; Leyton, J. V.; Maghera, S.; Deif, B.; Reilly, R. M.; Minden, M. D.; Keating, A. (2018). CD16(+)NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice. Haematologica, 103(10), 1720-1729. doi:10.3324/haematol.2017.187385

haNK Paper

Tomalka, A. G., Resto-Garay, I., Campbell, K. S., & Popkin, D. L. (2018). In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells. Front Immunol, 9, 2552. doi:10.3389/fimmu.2018.02552

Veterinary Paper

Addissie, S., & Klingemann, H. (2018). Cellular Immunotherapy of Canine Cancer. Vet Sci, 5(4). doi:10.3390/vetsci5040100

Veterinary Paper

Klingemann, H. (2018). Immunotherapy for Dogs: Running Behind Humans. Front Immunol, 9, 133. doi:10.3389/fimmu.2018.00133

haNK Paper

Friedman, J., Morisada, M., Sun, L., Moore, E. C., Padget, M., Hodge, J. W., . . . Allen, C. T. (2018). Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies. J Immunother Cancer, 6(1), 59. doi:10.1186/s40425-018-0374-2

haNK Poster

NANT Cancer Vaccine (NCV): An Orchestration of Immunogenic Cell Death by Overcoming Immune Suppression and Activating Natural Killer (NK) and T Cell Therapy in Patients with Greater than 3rd Line Metastatic Pancreatic Cancer; Tara Seery, Arvind Shinde, Mira Kistler, Lennie Sender, Anand Annamalai, Omid Jafari Frank Jones, John H. Lee, Patrick Soon-Shiong; Nov 2018

haNK Poster

NANT Cancer Vaccine (NCV): An Orchestration of Immunogenic Cell Death by Overcoming Immune Suppression and Activating Natural Killer (NK) and T Cell Therapy in Patients with Greater Than 3rd-Line Triple-Negative Breast Cancer (TNBC) or Head and Neck Squamous Cell Carcinoma (HNSCC); Chaitali Nangia, Mira Kistler, Lennie Sender, John H. Lee, Frank Jones, Patrick Soon-Shiong; Nov 2018

haNK Poster

Glipican-1 as a Novel Immunotherapeutic Target in Urological Cancers, ASCO; Douglas H. Campbell, Alexander B. Zaslavsky, Mackenzie Adams, Sandra Wissmueller, Hans G. Klingemann, Bradley J Walsh and Ganesh Palapattu; Minomic International Ltd; Department of Urology, University of Michigan; NantKwest Inc.; June 2018

taNK Poster

Providing a Homing Receptor for CAR Engineered NK Cells – Improving Cellular Immunotherapy for B-Cell Lymphomas; Nathan Schomer, MS, Laurent Boissel, PhD, Karen Jiang, PhD, Hans Klingemann, MD, PhD, John H. Lee, MD, F.A.C.S. and Patrick Soon-Shiong, MD, FRCS(C), F.A.C.S.; NantKwest, Inc., Culver City, CA

2017

haNK Paper

Jochems, C., Hodge, J. W., Fantini, M., Tsang, K. Y., Vandeveer, A. J., Gulley, J. L., & Schlom, J. (2017). ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody. Int J Cancer, 141(3), 583-593. doi:10.1002/ijc.30767

haNK Paper

Fujii, R., Schlom, J., & Hodge, J. W. (2017). A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab. J Neurosurg, 1-9. doi:10.3171/2017.1.JNS162610

taNK Paper

Zhang, C. O., P.; Oelsner, S.; Waldmann, A.; Lindner, A.; Tonn, T.; Wels, W. S. (2017). Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity. Front Immunol, 8, 533. doi:10.3389/fimmu.2017.00533

taNK Paper

Oelsner, S., Friede, M. E., Zhang, C., Wagner, J., Badura, S., Bader, P., . . . Wels, W. S. (2017). Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma. Cytotherapy, 19(2), 235-249. doi:10.1016/j.jcyt.2016.10.009

aNK Paper

Williams, B. A., Law, A. D., Routy, B., denHollander, N., Gupta, V., Wang, X. H., . . . Keating, A. (2017). A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy. Oncotarget, 8(51), 89256-89268. doi:10.18632/oncotarget.19204

aNK haNK & taNK Paper

Adusumilli, P. S., Cha, E., Cornfeld, M., Davis, T., Diab, A., Dubensky, T. W., Jr., . . . Chen, D. S. (2017). New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31(st)Annual Meeting of the Society for Immunotherapy of Cancer, 2016. J Immunother Cancer, 5, 50. doi:10.1186/s40425-017-0253-2

haNK Paper

Jochems, C., Tritsch, S. R., Pellom, S. T., Su, Z., Soon-Shiong, P., Wong, H. C., . . . Schlom, J. (2017). Analyses of functions of an anti-PD-L1/TGFbetaR2 bispecific fusion protein (M7824). Oncotarget, 8(43), 75217-75231. doi:10.18632/oncotarget.20680

taNK Poster

CD19 Chimeric Antigen Receptor (CAR) Engineered Natural Killer (NK) Cell Therapy: Novel “Off the Shelf” Immunotherapy in CD20 Resistant Bcell NonHodgkin Lymphoma (NHL) Cell Lines and a Human Lymphoma Xenograft Model; Sneha Purvey, Ravi Dashnamoorthy, Afshin Beheshti, Andreas Klein, Laurent Boissel,Saheli Sarkar, Tali Konry, and Andrew M Evens; Dec 2017

haNK Abstract & Oral

Preclinical characterization of a novel monoclonal antibody targeting a neo-antigen expressed in ovarian and GI malignancies; Kristen Zeligs, Philip M. Arlen, Kwong Tsang, Lidia Hernandez, Massimo Fantini, Christina M. Annunziata; Walter Reed National Military Medical Center, Bethesda, MD; Precision Biologics, Inc., Rockville, MD; National Cancer Institute, Bethesda, MD.

2016

haNK Paper

Jochems, C., Hodge, J. W., Fantini, M., Fujii, R., Morillon, Y. M., 2nd, Greiner, J. W., . . . Schlom, J. (2016). An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele. Oncotarget, 7(52), 86359-86373. doi:10.18632/oncotarget.13411

taNK Paper

Zhang, C., Burger, M. C., Jennewein, L., Genssler, S., Schonfeld, K., Zeiner, P., . . . Wels, W. S. (2016). ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma. J Natl Cancer Inst, 108(5). doi:10.1093/jnci/djv375

taNK Paper

Suck, G., Odendahl, M., Nowakowska, P., Seidl, C., Wels, W. S., Klingemann, H. G., & Tonn, T. (2016). NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy. Cancer Immunol Immunother, 65(4), 485-492. doi:10.1007/s00262-015-1761-x

taNK Paper

Romanski, A., Uherek, C., Bug, G., Seifried, E., Klingemann, H., Wels, W. S., . . . Tonn, T. (2016). CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. J Cell Mol Med, 20(7), 1287-1294. doi:10.1111/jcmm.12810

aNK Paper

Suck, G., Linn, Y. C., & Tonn, T. (2016). Natural Killer Cells for Therapy of Leukemia. Transfus Med Hemother, 43(2), 89-95. doi:10.1159/000445325

taNK Paper

Klingemann, H., Boissel, L., & Toneguzzo, F. (2016). Natural Killer Cells for Immunotherapy - Advantages of the NK-92 Cell Line over Blood NK Cells. Front Immunol, 7, 91; doi:10.3389/fimmu.2016.00091

taNK Paper

Genssler, S., Burger, M. C., Zhang, C., Oelsner, S., Mildenberger, I., Wagner, M., . . . Wels, W. S. (2016). Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival. Oncoimmunology, 5(4), e1119354. doi:10.1080/2162402X.2015.1119354

taNK Paper

Alkins, R., Burgess, A., Kerbel, R., Wels, W. S., & Hynynen, K. (2016). Early treatment of HER2-amplified brain tumors with targeted NK-92 cells and focused ultrasound improves survival. Neuro Oncol, 18(7), 974-981. doi:10.1093/neuonc/nov318

aNK Paper

Koehl, U., Kalberer, C., Spanholtz, J., Lee, D. A., Miller, J. S., Cooley, S., . . . Alici, E. (2016). Advances in clinical NK cell studies: Donor selection, manufacturing and quality control. Oncoimmunology, 5(4), e1115178. doi:10.1080/2162402X.2015.1115178

aNK Poster

Adoptive Cellular Therapy (ACT) With Allogeneic Activated Natural Killer (aNK) Cells in Patients With Advanced Merkel Cell Carcinoma (MCC): Preliminary Results of a Phase 2 Trial; Shailender Bhatia, Melissa Burgess, Hui Zhang, Tien Lee, Hans Klingemann, Patrick Soon-Shiong, Paul Nghiem, John M. Kirkwood

haNK Poster

A GMP-Grade IL-2 Independent NK Cell Line Expressing The High-affinity Fc-receptor (haNK) to Augment Antibody Therapeutics: Combination of haNK® With Anti-CD38 Monoclonal Antibody (Daratumumab) In Multiple Myeloma (2016); Boissel L, Klingemann H, Campbell K, Nichols K, Toneguzzo F, Khan J, Marcus, P, Williams BA, Keating A, and Soon-Shiong P, NantKwest, Inc., Cambridge, MA, USA; Fox Chase Cancer Center, Philadelphia, PA, USA; Princess Margaret Cancer Centre, Toronto, ON, Canada; NantKwest, Inc., Culver City, CA, USA; University California Los Angeles, CA, USA

haNK Poster

haNK, a cytotoxic human high affinity natural killer cell line, exerts enhanced ADCC mediated by avelumab (an anti-PD-L1 antibody) against multiple human tumor cell lines; Kwong Y. Tsang, Massimo Fantini, James W. Hodge, Rika Fujii, Ingrid Fernando, Caroline Jochems, Christopher R. Heery, James L. Gulley, Patrick Soon-Shiong, Jeffrey Schlom. Laboratory of Tumor Immunology and Biology and Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; NantKwest, Culver City, CA.

haNK Poster

High-affinity Activated Natural Killer (haNK) Cells Augment Trastuzumab Efficacy in a Mouse Model of HER2-positive Human Metastatic Breast Cancer; Shahrooz Rabizadeh, Longen Zhou, Frances Toneguzzo, Laurent Boissel, Patrick Soon-Shiong, Kayvan Niazi, Hans Klingemann; NantCell, Inc., Culver City, CA, NantBioscience, Inc., Culver City, CA, NantKwest., Inc, Culver City, CA

taNK Poster

Targeted NK cells display potent activity against glioblastoma and induce protective antitumor immunity; Congcong Zhang, Michael C. Burger, Lukas Jennewein, Anja Waldmann, Michel Mittelbronn, Torsten Tonn, Joachim P. Steinbach, Winfried S. Wels Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany; Institute for Neurooncology, Goethe University, Frankfurt am Main, Germany; German Cancer Consortium (DKTK), partner site Frankfurt/Mainz, Frankfurt am Main, Germany; Edinger Institute, Goethe University, Frankfurt am Main, Germany; German Red Cross Blood Donation Service North-East, Dresden, Germany

taNK Poster

Creating NK cell therapeutics with multiple targeting activities: Electroporation of mRNA for Chimeric Antigen Receptors (CARs) into human effector cell lines
Junaid Khan, Laurent Boissel, Hans Klingemann, Frances Toneguzzo, Patrick Soon-Shiong; Oct 2016

taNK Poster

Combination Therapy with Daratumumab and CAR-NK Targeting CS1 for Multiple Myeloma; Yibo Zhang, Lichao Chen, Yufeng Wang, Xinxin Li, Tiffany Hughes, Hans Klingemann, Don M. Benson and Jianhua Yu; Dec 2016

taNK Poster

Intra-tumor injection of CAR-engineered NK cells induces tumor regression and protection against tumor re-challenge; Laurent Boissel, PhD, Hans Klingemann, MD PhD, Junaid Khan, PhD, Patrick Soon-Shiong, MD FRCS (C), FACS. NK Society Meeting 2016

taNK Abstract + Oral

Intra-tumor injection of CAR-engineered NK cells induces tumor regression and protection against tumor re-challenge; Laurent Boissel, PhD, Hans Klingemann, MD PhD, Junaid Khan, PhD, Patrick Soon-Shiong, MD FRCS (C), FACS. ASH 2016

taNK Poster

Optimizing allogeneic natural killer cell reactivity by gene knock-out/knock-down of inhibitory receptors; Francisco Navarro, Taisia Shmushkovich, Monica Betancur-Boissel, Laurent Boissel, Hans Klingemann, Patrick Soon-Shiong; NantKwest, Inc. Woburn, MA and Culver City, CA, USA; Advirna/MirImmune, Cambridge, MA, USA

2015

taNK Paper

Schonfeld, K., Sahm, C., Zhang, C., Naundorf, S., Brendel, C., Odendahl, M., . . . Wels, W. S. (2015). Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol Ther, 23(2), 330-338. doi:10.1038/mt.2014.219

taNK Paper

Seidel, D. S., A.; Siebert, N.; Wels, W. S.; Reynolds, C. P.; Huebener, N.; Lode, H. N. (2015). Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma. Cancer Immunol Immunother, 64(5), 621-634. doi:10.1007/s00262-015-1669-5

taNK Paper

Klingemann, H. (2015). Challenges of cancer therapy with natural killer cells. Cytotherapy, 17(3), 245-249. doi:10.1016/j.jcyt.2014.09.007

taNK Poster

Novel Protocol Combining Metronomic Nant-Paclitaxel with HER2-Targeted Natural Killer Cells (innate Immunotherapy) for HER2 Positive Metastatic Breast Cancer; Shahrooz Rabizadeh, Barry Simon, Hans Klingemann, Deborah Sims, Raymond Weiss, Patrick Soon-Shiong; Dec 2015

taNK Poster

CD19 Target Activated Natural Killer (CD19.taNK) Cellular Therapy: A Novel immunotherapeutic Approach to the Treatment of Non-Hodkin Lymphoma (NHL); Ravi Dashnamoorthy, Afshin Beheshti, Saheli Sarkar, Pooja Sabhachandani, Frank C. Passero Jr., Sneha Purvey, Laurent Boissel, Tania Konry and Andrew M Evens; Dec 2015

haNK Poster

Development of an IL-2 independent NK cell line expressing high-affinity Fc-receptor to augment monoclonal antibody therapy Laurent Boissel, Kerry S. Campbell, Ashley M. James, Frances Toneguzzo, Hans Klingemann; Conkwest, Inc., Cardiff-by-the-Sea, CA USA; Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, PA USA

aNK Poster

NK-92 Therapy is Well Tolerated, Has Minimal Toxicity and Shows Efficacy in a Phase I Trial of Patients with Relapsed/Refractory Hematological Malignancies Relapsing after Autologous Stem Cell Transplantation; Brent Williams, MD PhD, Bertrand Routy, MD, Neal denHollander, PhD, Xing-Hua Wang, MD, Amelie Chaboureau, MSc, Sowmya Viswanathan, PhD, Armand Keating, MD; Cell Terapy Program, Princess Margaret Hospital Center, Toronto, ON , Canada, Department of Laboratory Medicine, University Health Network, Toronto, ON , Canada

aNK Poster

Development of a Perfused-Bioreactor Process for High-Density Culture of NK-92 Cells; Ricardo P. Baptista, Sowmya Viswanathan, Armand Keating, Peter W. Zandstra and Nicholas E. Timmins; Centre for Commercialization of Regenerative Medicine, Toronto, Canada, Cell Therapy Program, Princess Margaret Hospital, University Health Network, Toronto, Canada

aNK Poster

NK-92: An “off the shelf” target-specific cytotoxic cell therapeutic
Boissel L, Campbell, KS. Toneguzzo F, Nichols K and Klingemann H; Jun 2015